Cardiomyopathy Flashcards

1
Q

What is the prevalence of long QT syndrome in the general population?

A

1 in 2500

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What gene causes Long QT type 1? What is the mechanism?

A

KCNQ1

Loss of function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What gene causes Long QT type 2? What is the mechanism?

A

KCNH2

Loss of function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What gene causes Long QT type 3? What is the mechanism?

A

SCN5A

Gain of function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What gene causes Long QT type 5 and 6? What is the mechanism?

A

KNCE1 and KNCE2
Loss of function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What gene causes Long QT type 8 (Timothy syndrome)? What is the mechanism?

A

CACNA1C

Gain of function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What genes cause Brugada syndrome and what is the mechanism?

A

SCN5A (LoF)

KCND3 (GoF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What triggers lethal and non-lethal cardiac events in LQT1?

A

Exercise (75%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What triggers lethal and non-lethal cardiac events in LQT2?

A

Sleep, rest without arousal (63%)

Emotion (37%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What triggers lethal and non-lethal cardiac events in LQT3?

A

Sleep, rest without arousal (80%)

Emotion (15%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which gender has a higher lethal and non-lethal cardiac events in LQT starting in the mid-30s?

A

Females

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which beta blocker is not effective at treating LQTS?

A

Metoprolol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the Incidence of sudden death (per year) in Genotype-positive / Phenotype-positive individuals?

A

15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the Incidence of sudden death (per year) in Genotype-negative / Phenotype-positive individuals?

A

0.4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the Incidence of sudden death (per year) in Genotype-positive / Phenotype-negative individuals?

A

4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What should you avoid if you have LQTS?

A

Medications known to prolong QT interval
Rapid electrolyte shifts (fever, illness, dehydration, extreme sports)

17
Q

What is Hypertrophic Cardiomyopathy?

A

A disease in which the heart muscle becomes thickened (hypertrophied).

The thickened heart muscle can make it harder for the heart to pump blood.

18
Q

What syndromic genetic disorders have Hypertrophic Cardiomyopathy?

A
  • Infiltrative conditions
    -Glycogen storage diseases, Pompe’s disease, Danon disease, Fabry disease
    -Amyloidosis, sarcoidosis, etc.
  • Other systemic genetic conditions
    -Noonan syndrome, Costello syndrome, etc.
19
Q

What are the two most common genes associated with Hypertrophic Cardiomyopathy?

A

MYH7 and MYPBC3

20
Q

What are the phenotypic differences between MYH7 and MYPBC3 and TNNT2 mutations in HCM?

A
  • MYH7 tends to present at a young age with severe disease
  • MYPBC3 tends to present at an older age; if presenting at a young age often has very severe disease
  • TNNT2 has very little hypertrophy but greater cellular disarray and higher incidence of sudden death.
21
Q

What are the treatments in Hypertrophic Cardiomyopathy?

A

Goal is to decrease amount of obstruction
* Hydration status
* Beta blockers, Calcium channel blockers

Activity restrictions
* Shared decision model

Surgery

Heart transplant

Defibrillator for primary prevention in high-risk individuals

22
Q

What are some high risk signs in an adult with Hypertrophic Cardiomyopathy?

A
  • Family history of early sudden death
  • Syncope
  • Systolic dysfunction (EF <50%)
  • Documented ventricular tachycardia
  • Septal diameter of 30mm or greater
23
Q

What is caused by gain of function mutations in RYR2?

A

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

24
Q

What is caused by loss of function mutations in CASQ2?

A

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

25
Q

What can lead to an event in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)?

A

Exercise, emotion, high stress situations

26
Q

What is the treatment for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)?

A

Beta-blockers
Sodium-channel blockers

Left sympathetic denervation

ICD

(Early aggressive management warranted)

27
Q

What is Arrhythmogenic Right Ventricular Cardiomyopathy?

A
  • Fibrofatty replacement of myocardium
  • More commonly effects the Right Ventricle
  • Mean age of onset early 30’s
  • Presents earlier in athletes
  • “An over-use injury of the heart”
  • Palpitations or syncope is the most common presenting symptom
  • May present as sudden death
28
Q

What is the treatment in Arrhythmogenic Right Ventricular Cardiomyopathy?

A
  • Treatment first focused on addressing arrhythmias and avoiding sudden death
    -Anti-arrhythmic medications
    -Implantable-cardioverter defibrillator
  • Must avoid strenuous exercise or competitive athletics
29
Q

What are the two most common genes associated with Arrhythmogenic Right Ventricular Cardiomyopathy?

A

PKP2 and DSP

30
Q

What are the screening recommendation for Arrhythmogenic Right Ventricular Cardiomyopathy?

A
  • Genotype-positive family members
    -Should avoid strenuous exercise
    -Should be screened for disease every 12-18 months (age 10-50)
  • Gene-negative probands / genetic testing not performed
    -Counseled on symptoms
    -Should be screened for disease every 3-5 years (minimum) after age 10
31
Q

What is Brugada syndrome?

A

A rare but serious condition that affects the way electrical signals pass through the heart.

It can cause the heart to beat dangerously fast.